Supplement

You have full text access to this OnlineOpen article

Burden of cervical cancer in the United States, 1998–2003†‡

  1. Meg Watson MPH1,§,*,
  2. Mona Saraiya MD, MPH1,
  3. Vicki Benard PhD1,
  4. Steven S. Coughlin PhD, MPH1,
  5. Lisa Flowers MD2,
  6. Vilma Cokkinides PhD3,
  7. Molly Schwenn MD4,
  8. Youjie Huang MD, MPH, DrPh5,
  9. Anna Giuliano PhD6,¶

Article first published online: 3 NOV 2008

DOI: 10.1002/cncr.23756

Issue

Cancer

Cancer

Supplement: Assessing the Burden of HPV-Associated Cancers in the United States

Volume 113, Issue Supplement 10, pages 2855–2864, 15 November 2008

Additional Information

How to Cite

Watson, M., Saraiya, M., Benard, V., Coughlin, S. S., Flowers, L., Cokkinides, V., Schwenn, M., Huang, Y. and Giuliano, A. (2008), Burden of cervical cancer in the United States, 1998–2003. Cancer, 113: 2855–2864. doi: 10.1002/cncr.23756

Author Information

  1. 1

    Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia

  2. 2

    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Emory University School of Medicine, Atlanta, Georgia

  3. 3

    Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, Georgia

  4. 4

    Maine Cancer Registry, Maine Center for Disease Control and Prevention, Department of Health and Human Services, Augusta, Maine

  5. 5

    Chronic Disease Epidemiology Section, Bureau of Epidemiology, Florida Department of Health, Tallahassee, Florida

  6. 6

    Risk Assessment, Detection, and Intervention Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

  1. §

    Fax: (770) 488-4639.

  2. Dr. Giuliano has acted as a member of the Speakers Bureau and Advisory Board for Merck and Company and has received a research grant from the company.

*Epidemiology and Applied Research Branch, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway MS-K55, Atlanta, GA 30341

  1. †

    The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

  2. ‡

    This article is a US Government work and, as such, is in the public domain in the United States of America.

Publication History

  1. Issue published online: 3 NOV 2008
  2. Article first published online: 3 NOV 2008
  3. Manuscript Accepted: 7 MAY 2008
  4. Manuscript Revised: 6 MAY 2008
  5. Manuscript Received: 14 APR 2008

Funded by

  • Cooperative Agreement. Grant Number: U50 DP424071-04
  • Centers for Disease Control and Prevention

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (205K)

REFERENCES

  • 1
    Parkin DM,Bray F,Ferlay J,Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74–108.
    Direct Link:
  • 2
    US Cancer Statistics Working Group. United States Cancer Statistics: 2004 Incidence and Mortality. Atlanta, Ga: Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2007.
  • 3
    Sherman ME,Wang SS,Carreon J,Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States: relation to incidence and survival. Cancer. 2005; 103: 1258–1264.
    Direct Link:
  • 4
    Smith HO,Tiffany MF,Qualls CR,Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study. Gynecol Oncol. 2000; 78: 97–105.
  • 5
    Saraiya M,Ahmed F,Krishnan S,Richards T,Unger ER,Lawson H. Cervical cancer incidence in a prevaccine era—United States, 1998‒2002. Obstet Gynecol. 2007; 109: 360–370.
  • 6
    McDougall JA,Madeleine MM,Daling JR,Li CI. Racial and ethnic disparities in cervical cancer incidence rates in the United States, 1992‒2003. Cancer Causes Control. 2007; 18: 1175–1186.
  • 7
    Espey DK,Wu X,Swan J, et al. Annual report to the nation on the status of cancer, 1975–2004, featuring cancer in American Indians and Alaska Natives. Cancer. 2007; 110: 2119–2152.
    Direct Link:
  • 8
    Yabroff KR,Lawrence WF,King JC, et al. Geographic disparities in cervical cancer mortality: what are the roles of risk factor prevalence, screening, and use of recommended treatment? J Rural Health. 2005; 21: 149–157.
    Direct Link:
  • 9
    Walboomers JMM,Jacobs MV,Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12–19.
    Direct Link:
  • 10
    Cogliano V. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Human Papillomaviruses [90]. Lyon, France: World Health Organization, International Agency for Research on Cancer; 2007.
  • 11
    Munoz N,Castellsague X,de Gonzalez AB,Gissmann L. HPV in the etiology of human cancer. Vaccine. 2006; 24( suppl 3): S1–S10.
  • 12
    Wright TCJ,Massad LS,Dunton CJ,Spitzer M,Wilkinson EJ,Solomon D. 2006 Consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007; 197: 346–355.
  • 13
    Smith R,Cokkinides V,Eyre H. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin. 2006; 56: 11–25.
    Direct Link:
  • 14
    Paavonen J,Jenkins D,Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase 3 double-blind, randomised controlled trial. Lancet. 2007; 369: 2161–2170.
  • 15
    Villa LL,Costa RL,Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006; 95: 1459–1466.
  • 16
    US Cancer Statistics Working Group. United States Cancer Statistics: 2003 Incidence and Mortality. Atlanta, Ga: Centers for Disease Control and Prevention; 2006. Available at: http://www.cdc.gov/cancer/npcr/uscs/. Accessed October 23, 2007.
  • 17
    Watson M,Saraiya M,Ahmed F, et al. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer. 2008; 113( 10 suppl): 2841–2854.
    Direct Link:
  • 18
    Howe HL,Jamison M,Havener L,Chen VW,Ries L, and members of the NAACCR Collaborative Research Work Group. Site-specific Comparison of Summary Stage 1977 and Summary Stage 2000 Coding. Springfield, Ill: North American Association of Central Cancer Registries; 2005. Available at: http://www.naaccr.org/index.asp?Col_SectionKey=11&Col_ContentID=397. Accessed on February 11, 2007.
  • 19
    Tiwari RC,Clegg LX,Zou Z. Efficient interval estimation for age-adjusted cancer rates. Stat Methods Med Res. 2006; 15: 547–569.
  • 20
    North American Association of Central Cancer Registries (NAACCR) Latino Research Work Group. NAACCR Guideline for Enhancing Hispanic-Latino Identification: Revised NAACCR Hispanic/Latino Identification Algorithm [NHIA v2]. Springfield, Ill: North American Association of Central Cancer Registries; 2005.
  • 21
    Day JC. Population Projections of the United States by Age, Sex, Race, and Hispanic Origin: 1995 to 2050, U.S. Bureau of the Census, Current Population Reports, P25–1130. Washington, DC: US Government Printing Office; 1996.
  • 22
    Benard VB,Coughlin SS,Thompson T,Richardson LC. Cervical cancer incidence in the United States by area of residence, 1998‒2001. Obstet Gynecol. 2007; 110: 681–686.
  • 23
    Swan J,Breen N,Coates RJ,Rimer BK,Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003; 97: 1528–1540.
    Direct Link:
  • 24
    Benard VB,Lee NC,Piper M,Richardson L. Race-specific results of Papanicolaou testing and the rate of cervical neoplasia in the National Breast and Cervical Cancer Early Detection Program, 1991‒1998 (United States). Cancer Causes Control. 2001; 12: 61–68.
  • 25
    Bolen J,Adams M,Shenson D. Routine preventive services for older women: a composite measure highlights gaps in delivery. J Womens Health. 2007; 16: 583–593.
  • 26
    Benard VB,Lawson HW,Eheman CR,Anderson C,Helsel W. Adherence to guidelines for follow-up of low-grade cytologic abnormalities among medically underserved women. Obstet Gynecol. 2005; 105: 1323–1328.
  • 27
    Eggleston KS,Coker AL,Luchok KJ,Meyer TE. Adherence to recommendations for follow-up to abnormal Pap tests. Obstet Gynecol. 2007; 109: 1332–1341.
  • 28
    Eggleston KS,Coker AL,Das IP,Cordray ST,Luchok KJ. Understanding barriers for adherence to follow-up care for abnormal Pap tests. J Womens Health. 2007; 16: 311–330.
  • 29
    Tsui J,Saraiya M,Thompson T,Dey A,Richardson L. Cervical cancer screening among foreign-born women by birthplace and duration in the United States. J Womens Health. 2007; 16: 1447–1457.
  • 30
    Coughlin SS,Leadbetter S,Richards TB,Sabatino S. Contextual analysis of breast and cervical cancer screening and factors associated with health care access among United States women, 2002. Soc Sci Med. 2008; 66: 260–275.
  • 31
    Holt JB. The topography of poverty in the United States: a spatial analysis using county-level data from the Community Health Status Indicators project. Prev Chronic Dis [serial online]. 2007; 4: A111.
  • 32
    Ward E,Halpern M,Schrag N, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin. 2008; 58: 9–31.
    Direct Link:
  • 33
    Coughlin SS,King J,Richards TB,Ekwueme DU. Cervical cancer screening among women in metropolitan areas of the United States by individual-level and area-based measures of socioeconomic status, 2000 to 2002. Cancer Epidemiol Biomarkers Prev. 2006; 15: 2154–2159.
  • 34
    Becker TM,Espey DK,Lawson HW,Saraiya M,Jim MA,Waxman AG. Regional differences in cervical cancer incidence among American Indians and Alaska Natives, 1999‒2004. Cancer. 2008; 113( 5 suppl): 1234–1243.
    Direct Link:
  • 35
    Dunne EF,Unger ER,Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007; 297: 813–819.
  • 36
    Schiffman M,Castle PE,Jeronimo J,Rodriguez AC,Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007; 370: 890–907.
  • 37
    Castellsague X,Munoz N. Chapter 3: cofactors in human papillomavirus carcinogenesis—role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003;( 31): 20–28.
  • 38
    Parikh S,Brennan P,Boffetta P. Meta-analysis of social inequality and the risk of cervical cancer. Int J Cancer. 2003; 105: 687–691.
    Direct Link:
  • 39
    Benard VB,Johnson CJ,Thompson TD, et al. Examining the association between socio-economic factors and human papillomavirus-related cancers. Cancer. 2008; 113( 10 suppl): 2910–2918.
    Direct Link:
  • 40
    Farley J,Risinger JI,Rose GS,Maxwell GL. Racial disparities in blacks with gynecologic cancers. Cancer. 2007; 110: 234–243.
    Direct Link:
  • 41
    Akers A,Newmann S,Smith J. Factors underlying disparities in cervical cancer incidence, screening, and treatment in the United States. Curr Probl Cancer. 2007; 31: 157–181.
  • 42
    Castellsague X,Diaz M,De Sanjose S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006; 98: 303–315.
  • 43
    Lacey JVJr,Swanson CA,Brinton LA, et al. Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer. 2003; 98: 814–821.
    Direct Link:
  • 44
    Wang SS,Sherman ME,Silverberg SG, et al. Pathological characteristics of cervical adenocarcinoma in a multicenter US-based study. Gynecol Oncol. 2006; 103: 541–546.
  • 45
    Viswanathan AN,Deavers MT,Jhingran A,Ramirez PT,Levenback C,Eifel PJ. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol. 2004; 93: 27–33.
  • 46
    Ward E,Jemal A,Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004; 54: 78–93.
    Direct Link:
  • 47
    Merrill RM,Merrill AV,Mayer LS. Factors associated with no surgery or radiation therapy for invasive cervical cancer in black and white women. Ethn Dis. 2000; 10: 248–256.
  • 48
    YoungJL,RoffersSD,RiesLAG,FritzAG,HurlbutAA, eds. SEER Summary Staging Manual-2000: Codes and Coding Instructions. NIH Publication No. 01–4969. Bethesda, Md: National Cancer Institute; 2001.
  • 49
    Kinney W,Sawaya GF,Sung HY,Kearney KA,Miller M,Hiatt RA. Stage at diagnosis and mortality in patients with adenocarcinoma and adenosquamous carcinoma of the uterine cervix diagnosed as a consequence of cytologic screening. Acta Cytol. 2003; 47: 167–171.
  • 50
    US Cancer Statistics Working Group. United States Cancer Statistics: 1999‒2004 incidence and mortality web-based report. Bethesda, Md: Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2007. Available at: www.cdc.gov/uscs. Accessed on March 25, 2008.
  • 51
    Thoburn KK,German RR,Lewis M,Nichols PJ,Ahmed F,Jackson-Thompson J. Case completeness and data accuracy in the Centers for Disease Control and Prevention's National Program of Cancer Registries. Cancer. 2007; 109: 1607–1616.
    Direct Link:
  • 52
    Merrill RM. Impact of hysterectomy and bilateral oophorectomy on race-specific rates of corpus, cervical, and ovarian cancers in the United States. Ann Epidemiol. 2006; 16: 880–887.
  • 53
    Phillips J. Summary Stage: Data Effects of the Changes in 2000. Springfield, Ill: North American Association of Central Cancer Registries; 2003.
View Full Article (HTML) Get PDF (205K)